BioCentury
ARTICLE | Clinical News

Nabi reports Phase III

September 19, 2000 7:00 AM UTC

NABI said preliminary data from a Phase III trial in 1,804 end-stage renal patients showed its StaphVax Staphylococcus aureus capsular polysaccharide conjugate vaccine did not significantly reduce blood stream infections at one year, the primary end point of the study. Data from the placebo-controlled, double blind trial showed 27 S. aureus bacteremias in the StaphVax group compared to 37 in the placebo group, or a 26 percent reduction in bacteremias (p=0.228). The reduction in bacteremias was significant at 10 months, and the company that based on those results it believes an S. aureus vaccine is feasible. Data were presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Toronto. ...